Anavex Life Sciences, a clinical stage biopharmaceutical company that develops drugs for treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s and multiple sclerosis, said it signed an agreement under which Biogen (BIIB) will test its leading drug candidate.
The company said Biogen will test its Anavex 2-73 drug that’s designed to battle demyelinating diseases such as multiple sclerosis, which requires understanding of why remyelination fails. The studies will examine the therapeutic role Anavex 2-73 may play in permitting remyelination.
Anavex 273 is currently in a Phase 2a clinical trial for Alzheimer’s disease after completing Phase 1 trials with a clean safety profile. Pre-clinical studies showed the drug can halt or reverse the course of Alzheimer’s. The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex a research grant to develop the drug for for the treatment of Parkinson’s disease, the company said.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.